Grifols, S.A.
Sociedad Anónima
Traded as
ISINES0171996012 Edit this on Wikidata
IndustryPharmaceuticals, chemicals
HeadquartersBarcelona, Spain
Key people
Víctor Grífols (Chairman and CEO)
ProductsPlasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals
  • Increase €3,934.6 million (2015)
  • €3,355.4 million (2014) [1]:8
  • Increase €970.4 million (2015)
  • €857.7 million (2014) [1]:8
  • Increase €532.1 million (2015)
  • €470.3 million (2014)[1]:8
Total assets
  • Increase €9,601.7 million (2015)
  • €8,449.7 million (2014)[1]:6
Total equity
  • Increase €3,301.4 million (2015)
  • €2,662.9 million (2014)[1]:7
Number of employees
  • Increase 21,500 (2019, average) [1]:64

Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide,[2][3] the company also supplies devices, instruments, and reagents for clinical testing laboratories.

Main products

Grifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.

Main operations

In 2007 the company had 3.6 million litres per year of blood fractionation capacity from three plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year), another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres), and a site in Clayton, NC. In the United States the company owns 153 plasmapheresis centres, where it collects around 5.8 million litres of plasma per year.


Grifols was listed on the Madrid Stock Exchange in May 2006.[4] The stock became part of the IBEX 35 index in January 2008.


Human immunoglobulin for anti-tetanus use and antithrombin produced by Grifols.

Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr José A. Grifols Roig, a hematologist and scientist. His son, Dr José A. Grífols Lucas was the first researcher to publish the plasmapheresis procedure in 1952.[5] The company introduced its liquid IVIG product into the European market in the mid-1990s.

Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A.[6] In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion.[7] On May 17, 2006, Grifols securities were listed on Spain’s Mercado Continuo.[8]

In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics (the former plasma business of Bayer HealthCare LLC, Biological Products Division)[9] for $3,1 billion but was stopped by the Federal Trade Commission.[10] On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[11]

Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion".[3] This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.[3]

In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's."[12]

In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion[13]


  1. ^ a b c d e f "Group annual consolidated accounts, auditors' report and directors' report for the financial year 2015". Grifols. Retrieved 2016-06-10.[self-published source]
  2. ^ Smyth, Sharon; Gore, Gareth (23 June 2008). "Santander, Sabadell, Sol Melia, Urbas: Iberia Preview". Bloomberg. Archived from the original on 23 October 2012. Retrieved 2009-01-18.
  3. ^ a b c Staff (December 2013). "Novartis Sells Blood Transfusion Dx Unit to Grifols". Genetic Engineering & Biotechnology News (Paper). 33 (21). p. 10.
  4. ^ Dowsett, Sonya (19 January 2007). "Blood firm Grifols sees 2006 sales up 22 pct". Reuters. Retrieved 2009-01-18.
  5. ^ Grífols-Lucas, JA (1952). "Use of plasmapheresis in blood donors". British Medical Journal. 1 (4763): 854. doi:10.1136/bmj.1.4763.854. PMC 2023259. PMID 14916171.
  6. ^ "Grifols S.A. (formerly Probitas Pharma S.A.) And Subsidiaries: Consolidated Annual Accounts prepared in accordance with International Financial Reporting Standards as adopted for use in the European Union and Consolidated Directors' Report". 31 December 2005. Retrieved 2016-02-03.[self-published source]
  7. ^ "Mitsubishi Pharma to Withdraw from US Plasma Fractionation Business as US Subsidiary Transfers Operations" (Press release). Mitsubishi Pharma Corporation. 10 April 2003. Retrieved 2016-02-03.
  8. ^ Staff (1 May 2006). "News in brief: Third time lucky for Grifols". Financial News. London. Retrieved 2016-02-03.
  9. ^ "Announcing the Launch of Talecris Biotherapeutics" (Press release). Talecris. 1 April 2005. Retrieved 2016-02-03 – via BusinessWire.
  10. ^ "FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics". 2009-05-27. Retrieved 2016-02-03.
  11. ^ Wolf, Alan M. (2011-06-02). "Spanish buyer set to take over Talecris". News & Observer. Archived from the original on 2011-06-05. Retrieved 2011-06-02.
  12. ^ Staff (1 April 2015). "Grifols Makes $37.5M Investment in Alkahest". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  13. ^

Further reading

External links

This page was last updated at 2021-01-20 03:25 UTC. Update now. View original page.

All our content comes from Wikipedia and under the Creative Commons Attribution-ShareAlike License.


If mathematical, chemical, physical and other formulas are not displayed correctly on this page, please useFirefox or Safari